We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
-3.82%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$9.49M
Cap. Flow
-$2.21M
Cap. Flow %
-1.66%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$6.92M
2
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$445K

Top Sells

Rank Stock Value
1
TLOG
TetraLogic Pharmaceuticals Corporation
TLOG
+$8.04M
2
AERI
Aerie Pharmaceuticals
AERI
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
1
DELISTED
NanoString Technologies, Inc.
NSTG
$60.3M 45.24%
3,959,440
– –
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$21.3M 16.02%
2,153,092
– –
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$18.7M 14.02%
273,077
– –
ATXS
4
DELISTED
Astria Therapeutics
ATXS
$13.9M 10.42%
45,875
– –
VBIV
5
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$12.2M 9.13%
172,434
+6,731
+4% +$445K
EPIX
6
DELISTED
ESSA Pharma
EPIX
$6.89M 5.18%
+106,061
New +$6.92M
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
– –
-63,017
Closed -$1.53M
TLOG
8
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
– –
-4,644,705
Closed -$8.04M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q1 2016 Portfolio in Review

As of Q1 2016, Clarus Ventures held 8 positions worth $133M, down 6.7% from $143M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures's Q1 2016 filing shows 1 new, 1 increased and 2 closed positions. Its largest new stake was ESSA Pharma: 106,061 shares worth $6.89M. The largest sale was TetraLogic Pharmaceuticals Corporation, an estimated $8.04M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures's largest Q1 2016 buy was ESSA Pharma: 106,061 shares worth $6.89M.
  • Clarus Ventures added most to VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2016, an estimated $445K increase.
  • Clarus Ventures fully exited TetraLogic Pharmaceuticals Corporation in Q1 2016, selling an estimated $8.04M.
  • Clarus Ventures's ten largest holdings make up 100% of its $133M portfolio in Q1 2016.
  • Clarus Ventures opened 1 new position and closed 2 in Q1 2016.
  • Clarus Ventures's portfolio value fell 6.7% quarter-over-quarter to $133M.

Based on Clarus Ventures's 13F filing for Q1 2016, filed 22 Apr 2016.